{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T14:58:08Z","timestamp":1785164288404,"version":"3.55.0"},"reference-count":99,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100009307","name":"Parkinson Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009307","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000156","name":"Fonds de Recherche Qu\u00e9bec \u2013 Sant\u00e9, Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000156","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000038","name":"Natural Sciences and Engineering Research Council of Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000038","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012479","name":"Weston Brain Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012479","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000864","name":"Michael J Fox Foundation for Parkinson's Research, United States","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000864","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Healthy Brains for Healthy Lives, Canada"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1016\/j.neuropharm.2019.107725","type":"journal-article","created":{"date-parts":[[2019,7,25]],"date-time":"2019-07-25T11:33:43Z","timestamp":1564054423000},"page":"107725","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"special_numbering":"C","title":["Activation of mGlu2\/3 receptors, a novel therapeutic approach to alleviate dyskinesia and psychosis in experimental parkinsonism"],"prefix":"10.1016","volume":"158","author":[{"given":"Imane","family":"Frouni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9869-6752","authenticated-orcid":false,"given":"Adjia","family":"Hamadjida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Kwan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"B\u00e9dard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vaidehi","family":"Nafade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fleur","family":"Gaudette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen G.","family":"Nuara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jim C.","family":"Gourdon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis","family":"Beaudry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Huot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2019.107725_bib1","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1097\/YIC.0000000000000117","article-title":"Metabotropic glutamate2\/3 receptor agonism facilitates autonomic recovery after pharmacological panic challenge in healthy humans","volume":"31","author":"Agorastos","year":"2016","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2019.107725_bib2","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1002\/mds.1090","article-title":"Frequency of levodopa\u2010related dyskinesias and motor fluctuations as estimated from the cumulative literature","volume":"16","author":"Ahlskog","year":"2001","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuropharm.2019.107725_bib3","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1056\/NEJM199307153290303","article-title":"Clozapine-induced agranulocytosis--incidence and risk factors in the United States","volume":"329","author":"Alvir","year":"1993","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.neuropharm.2019.107725_bib4","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/jps.24226","article-title":"Relative contributions of presystemic and systemic peptidases to oral exposure of a novel metabotropic glutamate 2\/3 receptor agonist (LY404039) after oral administration of prodrug pomaglumetad methionil (LY2140023)","volume":"104","author":"Annes","year":"2015","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.neuropharm.2019.107725_bib5","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1097\/00004850-200511000-00001","article-title":"Metabotropic glutamate II receptor agonists in panic disorder: a double blind clinical trial with LY354740","volume":"20","author":"Bergink","year":"2005","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2019.107725_bib6","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1124\/jpet.118.247650","article-title":"Pharmacokinetic\/Pharmacodynamic correlation analysis of amantadine for levodopa-induced dyskinesia","volume":"367","author":"Brigham","year":"2018","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2019.107725_bib7","series-title":"Maladaptive Striatal Plasticity in L-DOPA-Induced Dyskinesia. Progress in Brain Research","first-page":"209","author":"Cenci","year":"2010"},{"key":"10.1016\/j.neuropharm.2019.107725_bib8","doi-asserted-by":"crossref","DOI":"10.1002\/0471142301.ns0925s41","article-title":"Ratings of L-DOPA-induced dyskinesia in the unilateral 6-OHDA lesion model of Parkinson's disease in rats and mice","author":"Cenci","year":"2007","journal-title":"Curr. Protoc. Neurosci."},{"key":"10.1016\/j.neuropharm.2019.107725_bib9","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.tips.2017.03.008","article-title":"mGlu2\/3 receptor antagonists as novel antidepressants","volume":"38","author":"Chaki","year":"2017","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.neuropharm.2019.107725_bib10","doi-asserted-by":"crossref","first-page":"S86","DOI":"10.1016\/S1471-1931(00)00018-5","article-title":"Striatal dopamine-and glutamate-mediated dysregulation in experimental parkinsonism","volume":"23","author":"Chase","year":"2000","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.neuropharm.2019.107725_bib11","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S0140-6736(13)62106-6","article-title":"Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial","volume":"383","author":"Cummings","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.neuropharm.2019.107725_bib12","first-page":"755","article-title":"LY-544344","volume":"8","author":"Danysz","year":"2005","journal-title":"Eli Lilly. IDrugs"},{"key":"10.1016\/j.neuropharm.2019.107725_bib13","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.bbr.2007.01.013","article-title":"Modulation of L-DOPA-induced abnormal involuntary movements by clinically tested compounds: further validation of the rat dyskinesia model","volume":"179","author":"Dekundy","year":"2007","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neuropharm.2019.107725_bib14","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1016\/j.neuropharm.2012.01.010","article-title":"Heterocomplex formation of 5-HT2A-mGlu2 and its relevance for cellular signaling cascades","volume":"62","author":"Delille","year":"2012","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2019.107725_bib15","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.neuropharm.2017.10.026","article-title":"Functional partnership between mGlu3 and mGlu5 metabotropic glutamate receptors in the central nervous system","volume":"128","author":"Di Menna","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2019.107725_bib16","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1038\/sj.npp.1301531","article-title":"Efficacy and tolerability of an mGlu2\/3 agonist in the treatment of generalized anxiety disorder","volume":"33","author":"Dunayevich","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2019.107725_bib17","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1212\/01.WNL.0000110317.52453.6C","article-title":"Clozapine improves dyskinesias in Parkinson disease: a double-blind, placebo-controlled study","volume":"62","author":"Durif","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.neuropharm.2019.107725_bib18","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1002\/mds.27372","article-title":"International Parkinson and movement disorder society evidence-based medicine review: update on treatments for the motor symptoms of Parkinson's disease","volume":"33","author":"Fox","year":"2018","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuropharm.2019.107725_bib19","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1017\/S0317167100009707","article-title":"Neuropsychiatric behaviors in the MPTP marmoset model of Parkinson's disease","volume":"37","author":"Fox","year":"2010","journal-title":"Can. J. Neurol. Sci."},{"key":"10.1016\/j.neuropharm.2019.107725_bib20","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1001\/archneur.63.9.1343","article-title":"Dopamine receptor agonists and levodopa and inducing psychosis-like behavior in the MPTP primate model of Parkinson disease","volume":"63","author":"Fox","year":"2006","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.neuropharm.2019.107725_bib21","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1016\/S0140-6736(99)00860-0","article-title":"Clozapine in drug-induced psychosis in Parkinson\u2019s disease. The French clozapine Parkinson study group","volume":"353","author":"French Clozapine Parkinson Study Group","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.neuropharm.2019.107725_bib22","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.cell.2011.09.055","article-title":"Decoding the signaling of a GPCR heteromeric complex reveals a unifying mechanism of action of antipsychotic drugs","volume":"147","author":"Fribourg","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.neuropharm.2019.107725_bib23","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1111\/j.1600-0404.1991.tb04918.x","article-title":"Psychotic complications of long\u2010term levodopa treatment of Parkinson's disease","volume":"84","author":"Friedman","year":"1991","journal-title":"Acta Neurol. Scand."},{"issue":"2","key":"10.1016\/j.neuropharm.2019.107725_bib24","first-page":"435","article-title":"Effect of the selective 5-HT2A receptor antagonist EMD-281,014 on L-DOPA-induced abnormal involuntary movements in the 6-OHDA-lesioned rat","volume":"237","author":"Frouni","year":"2018","journal-title":"Exp. Brain Res."},{"key":"10.1016\/j.neuropharm.2019.107725_bib25","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/mp.2009.108","article-title":"Abnormal prefrontal activation directly related to pre-synaptic striatal dopamine dysfunction in people at clinical high risk for psychosis","volume":"16","author":"Fusar-Poli","year":"2011","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2019.107725_bib26","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.jchromb.2017.07.007","article-title":"Development and validation of a high-performance liquid chromatography-tandem mass spectrometry method to quantify LY-354,740 in rat and marmoset plasma","volume":"1061\u20131062","author":"Gaudette","year":"2017","journal-title":"J Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.neuropharm.2019.107725_bib27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jchromb.2018.06.036","article-title":"Development of a selective and sensitive high-performance liquid chromatography-tandem mass spectrometry assay to support pharmacokinetic studies of LY-487,379 in rat and marmoset","volume":"1093\u20131094","author":"Gaudette","year":"2018","journal-title":"J Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.neuropharm.2019.107725_bib28","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/nature06612","article-title":"Identification of a serotonin\/glutamate receptor complex implicated in psychosis","volume":"452","author":"Gonzalez-Maeso","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2019.107725_bib29","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1007\/s00213-003-1444-8","article-title":"Anxiolytic effects of a novel group II metabotropic glutamate receptor agonist (LY354740) in the fear-potentiated startle paradigm in humans","volume":"168","author":"Grillon","year":"2003","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.neuropharm.2019.107725_bib30","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1007\/s00210-018-1549-6","article-title":"Nefazodone reduces dyskinesia, but not psychosis-like behaviours, in the parkinsonian marmoset","volume":"391","author":"Hamadjida","year":"2018","journal-title":"Naunyn Schmiedebergs Arch. Pharmacol."},{"key":"10.1016\/j.neuropharm.2019.107725_bib31","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.neuropharm.2018.06.038","article-title":"The highly selective 5-HT2A antagonist EMD-281,014 reduces dyskinesia and psychosis in the l-DOPA-treated parkinsonian marmoset","volume":"139","author":"Hamadjida","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2019.107725_bib32","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.pnpbp.2017.09.001","article-title":"The effect of mianserin on the severity of psychosis and dyskinesia in the parkinsonian marmoset","volume":"81","author":"Hamadjida","year":"2018","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2019.107725_bib33","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1007\/s00702-017-1830-8","article-title":"Trazodone alleviates both dyskinesia and psychosis in the parkinsonian marmoset model of Parkinson's disease","volume":"125","author":"Hamadjida","year":"2018","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.neuropharm.2019.107725_bib34","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1007\/s00213-017-4530-z","article-title":"The effect of mirtazapine on dopaminergic psychosis and dyskinesia in the parkinsonian marmoset","volume":"234","author":"Hamadjida","year":"2017","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.neuropharm.2019.107725_bib35","doi-asserted-by":"crossref","first-page":"511","DOI":"10.3233\/JPD-171134","article-title":"ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson's disease (EASE LID 2 study): interim results of an open-label safety study","volume":"7","author":"Hauser","year":"2017","journal-title":"J. Parkinson's Dis."},{"issue":"1","key":"10.1016\/j.neuropharm.2019.107725_bib36","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s40262-018-0663-4","article-title":"Pharmacokinetics of ADS-5102 (amantadine) extended release capsules administered once daily at bedtime for the treatment of dyskinesia","volume":"58","author":"Hauser","year":"2019","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.neuropharm.2019.107725_bib37","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1002\/mds.20324","article-title":"Sydney Multicenter Study of Parkinson's disease: non-L-dopa-responsive problems dominate at 15 years","volume":"20","author":"Hely","year":"2005","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuropharm.2019.107725_bib38","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1124\/jpet.104.066191","article-title":"Levetiracetam potentiates the antidyskinetic action of amantadine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned primate model of Parkinson's disease","volume":"310","author":"Hill","year":"2004","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2019.107725_bib39","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1002\/mds.23083","article-title":"Increased 5-HT2A receptors in the temporal cortex of parkinsonian patients with visual hallucinations","volume":"25","author":"Huot","year":"2010","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuropharm.2019.107725_bib40","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0045587","article-title":"The monoamine Re-uptake inhibitor UWA-101 improves motor fluctuations in the MPTP-lesioned common marmoset","volume":"7","author":"Huot","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.neuropharm.2019.107725_bib41","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1097\/FBP.0000000000000096","article-title":"L-745,870 reduces the expression of abnormal involuntary movements in the 6-OHDA-lesioned rat","volume":"26","author":"Huot","year":"2015","journal-title":"Behav. Pharmacol."},{"key":"10.1016\/j.neuropharm.2019.107725_bib42","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.neuropharm.2012.06.012","article-title":"L-DOPA pharmacokinetics in the MPTP-lesioned macaque model of Parkinson's disease","volume":"63","author":"Huot","year":"2012","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2019.107725_bib43","doi-asserted-by":"crossref","first-page":"7190","DOI":"10.1523\/JNEUROSCI.1171-11.2011","article-title":"Characterization of 3,4-methylenedioxymethamphetamine (MDMA) enantiomers in vitro and in the MPTP-lesioned primate: R-MDMA reduces severity of dyskinesia, whereas S-MDMA extends duration of ON-time","volume":"31","author":"Huot","year":"2011","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2019.107725_bib44","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.neuropharm.2014.01.012","article-title":"UWA-121, a mixed dopamine and serotonin re-uptake inhibitor, enhances L-DOPA anti-parkinsonian action without worsening dyskinesia or psychosis-like behaviours in the MPTP-lesioned common marmoset","volume":"82","author":"Huot","year":"2014","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2019.107725_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.neurobiolaging.2010.04.035","article-title":"5-HT2A receptor levels increase in MPTP-lesioned macaques treated chronically with L-DOPA","volume":"33","author":"Huot","year":"2012","journal-title":"Neurobiol. Aging"},{"issue":"7 Suppl. l","key":"10.1016\/j.neuropharm.2019.107725_bib46","article-title":"Early amantadine treatment does not delay onset of dyskinesias in Parkinson's disease","volume":"80","author":"Jahangirvand","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.neuropharm.2019.107725_bib47","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1124\/dmd.30.1.27","article-title":"The disposition, metabolism, and pharmacokinetics of a selective metabotropic glutamate receptor agonist in rats and dogs","volume":"30","author":"Johnson","year":"2002","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.neuropharm.2019.107725_bib48","doi-asserted-by":"crossref","first-page":"3189","DOI":"10.1021\/jm034015u","article-title":"Discovery of allosteric potentiators for the metabotropic glutamate 2 receptor: synthesis and subtype selectivity of N-(4-(2-methoxyphenoxy)phenyl)-N-(2,2,2- trifluoroethylsulfonyl)pyrid-3-ylmethylamine","volume":"46","author":"Johnson","year":"2003","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.neuropharm.2019.107725_bib49","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1124\/jpet.110.166629","article-title":"Reduction of L-DOPA-induced dyskinesia by the selective metabotropic glutamate receptor 5 antagonist 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease","volume":"333","author":"Johnston","year":"2010","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2019.107725_bib50","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.biopsych.2015.01.014","article-title":"The novel metabotropic glutamate receptor 2 positive allosteric modulator, AZD8529, decreases nicotine self-administration and relapse in squirrel monkeys","volume":"78","author":"Justinova","year":"2015","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2019.107725_bib51","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1007\/s00213-004-2025-1","article-title":"Effects of a metabotropic glutamate(2\/3) receptor agonist (LY544344\/LY354740) on panic anxiety induced by cholecystokinin tetrapeptide in healthy humans: preliminary results","volume":"179","author":"Kellner","year":"2005","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.neuropharm.2019.107725_bib52","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.pnpbp.2016.01.009","article-title":"Efficacy and safety of an adjunctive mGlu2 receptor positive allosteric modulator to a SSRI\/SNRI in anxious depression","volume":"67","author":"Kent","year":"2016","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2019.107725_bib53","doi-asserted-by":"crossref","first-page":"65","DOI":"10.14802\/jmd.18005","article-title":"Amantadine and the risk of dyskinesia in patients with early Parkinson's disease: an open-label, pragmatic trial","volume":"11","author":"Kim","year":"2018","journal-title":"J. Mov. Disord."},{"key":"10.1016\/j.neuropharm.2019.107725_bib54","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1002\/mds.23867","article-title":"Synergistic antidyskinetic effects of topiramate and amantadine in animal models of Parkinson's disease","volume":"26","author":"Kobylecki","year":"2011","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuropharm.2019.107725_bib55","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s00213-004-1982-8","article-title":"Preliminary evidence of attenuation of the disruptive effects of the NMDA glutamate receptor antagonist, ketamine, on working memory by pretreatment with the group II metabotropic glutamate receptor agonist, LY354740, in healthy human subjects","volume":"179","author":"Krystal","year":"2005","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.neuropharm.2019.107725_bib56","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s00221-018-5434-9","article-title":"5-HT2A blockade for dyskinesia and psychosis in Parkinson's disease: is there a limit to the efficacy of this approach? A study in the MPTP-lesioned marmoset and a literature mini-review","volume":"237","author":"Kwan","year":"2019","journal-title":"Exp. Brain Res."},{"key":"10.1016\/j.neuropharm.2019.107725_bib57","article-title":"Pharmacological and pharmacokinetic properties of JNJ-40411813, a positive allosteric modulator of the mGlu2 receptor","volume":"3","author":"Lavreysen","year":"2015","journal-title":"Pharmacol. Res. Perspect."},{"key":"10.1016\/j.neuropharm.2019.107725_bib58","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1124\/jpet.113.204990","article-title":"Pharmacological characterization of JNJ-40068782, a new potent, selective, and systemically active positive allosteric modulator of the mGlu2 receptor and its radioligand [3H]JNJ-40068782","volume":"346","author":"Lavreysen","year":"2013","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2019.107725_bib59","first-page":"294","article-title":"The mGlu2\/3 receptor agonist, LY354740, reduces panic anxiety induced by a CO2 challenge in patients diagnosed with panic disorder [Abstract]","volume":"43","author":"Levine","year":"2002","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2019.107725_bib60","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.expneurol.2015.08.019","article-title":"LY395756, an mGluR2 agonist and mGluR3 antagonist, enhances NMDA receptor expression and function in the normal adult rat prefrontal cortex, but fails to improve working memory and reverse MK801-induced working memory impairment","volume":"273","author":"Li","year":"2015","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.neuropharm.2019.107725_bib61","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.ddstr.2006.10.018","article-title":"Metabotropic glutamate receptor targets for neuropsychiatric disorders","volume":"3","author":"Linden","year":"2006","journal-title":"Drug Discov. Today Ther. Strat."},{"key":"10.1016\/j.neuropharm.2019.107725_bib62","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.schres.2016.02.001","article-title":"AZD8529, a positive allosteric modulator at the mGluR2 receptor, does not improve symptoms in schizophrenia: a proof of principle study","volume":"172","author":"Litman","year":"2016","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.neuropharm.2019.107725_bib63","first-page":"39","article-title":"Plasma clozapine levels and the treatment of L-DOPA-induced psychosis in Parkinson's disease. A high potency effect of clozapine","volume":"12","author":"Meltzer","year":"1995","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2019.107725_bib64","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1097\/01.wnf.0000136891.17006.ec","article-title":"Quetiapine and clozapine in parkinsonian patients with dopaminergic psychosis","volume":"27","author":"Morgante","year":"2004","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.neuropharm.2019.107725_bib65","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1176\/ajp.152.10.1444","article-title":"D1, D2, and 5-HT2 receptor occupancy in relation to clozapine serum concentration: a PET study of schizophrenic patients","volume":"152","author":"Nordstrom","year":"1995","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.neuropharm.2019.107725_bib66","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/j.1469-8749.2001.tb04139.x","article-title":"Pharmacology and neuroprotective actions of mGlu receptor ligands","volume":"43","author":"O'Neill","year":"2001","journal-title":"Dev. Med. Child Neurol."},{"key":"10.1016\/j.neuropharm.2019.107725_bib67","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1002\/mds.27131","article-title":"Randomized, placebo-controlled trial of ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson's disease (EASE LID 3)","volume":"32","author":"Oertel","year":"2017","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuropharm.2019.107725_bib68","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1002\/mds.26159","article-title":"Amantadine extended release for levodopa-induced dyskinesia in Parkinson's disease (EASED Study)","volume":"30","author":"Pahwa","year":"2015","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuropharm.2019.107725_bib69","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.ejphar.2014.08.004","article-title":"The H3 receptor agonist immepip does not affect l-dopa-induced abnormal involuntary movements in 6-OHDA-lesioned rats","volume":"741","author":"Papathanou","year":"2014","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2019.107725_bib70","doi-asserted-by":"crossref","first-page":"3224","DOI":"10.1111\/j.1460-9568.2012.08243.x","article-title":"Anti-dyskinetic mechanisms of amantadine and dextromethorphan in the 6-OHDA rat model of Parkinson's disease: role of NMDA vs. 5-HT1A receptors","volume":"36","author":"Paquette","year":"2012","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.neuropharm.2019.107725_bib71","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1056\/NEJM199903113401003","article-title":"Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson\u2019s disease. The Parkinson Study Group","volume":"340","author":"Parkinson Study Group","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.neuropharm.2019.107725_bib72","series-title":"The Rat Brain in Stereotaxic Coordinates: Compact","author":"Paxinos","year":"2017"},{"key":"10.1016\/j.neuropharm.2019.107725_bib73","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1093\/brain\/awf269","article-title":"Striatal metabotropic glutamate receptor function following experimental parkinsonism and chronic levodopa treatment","volume":"125","author":"Picconi","year":"2002","journal-title":"Brain"},{"key":"10.1016\/j.neuropharm.2019.107725_bib74","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1111\/j.1532-5415.1975.tb00187.x","article-title":"Visual hallucinations and delirium during treatment with amantadine (Symmetrel)","volume":"23","author":"Postma","year":"1975","journal-title":"J. Am. Geriatr. Soc."},{"key":"10.1016\/j.neuropharm.2019.107725_bib75","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1002\/mds.21803","article-title":"A systematic review of prevalence studies of depression in Parkinson's disease","volume":"23","author":"Reijnders","year":"2008","journal-title":"Mov. Disord."},{"issue":"14 Suppl. l","key":"10.1016\/j.neuropharm.2019.107725_bib76","first-page":"188","article-title":"De-novo amantadine treatment delays onset of dyskinesias in patients with Parkinson disease (I3-5A) [Abstract]","volume":"84","author":"Relja","year":"2015","journal-title":"Neurology"},{"issue":"Suppl. 1","key":"10.1016\/j.neuropharm.2019.107725_bib77","first-page":"S382","article-title":"De-novo amantadine treatment prevents and delays onset of dyskinesias in Parkinson's disease [Abstract]","volume":"29","author":"Relja","year":"2014","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuropharm.2019.107725_bib78","first-page":"653","article-title":"ACP-103, a 5-HT2A receptor inverse agonist","volume":"7","author":"Roberts","year":"2006","journal-title":"Curr. Opin. Investig. Drugs"},{"key":"10.1016\/j.neuropharm.2019.107725_bib79","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1124\/jpet.106.110809","volume":"321","author":"Rorick-Kehn","year":"2007","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2019.107725_bib80","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1124\/jpet.105.091926","article-title":"Improved bioavailability of the mGlu2\/3 receptor agonist LY354740 using a prodrug strategy: in vivo pharmacology of LY544344","volume":"316","author":"Rorick-Kehn","year":"2006","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2019.107725_bib81","series-title":"Clinical Pharmacokinetics: Concepts and Application","author":"Rowland","year":"1995"},{"key":"10.1016\/j.neuropharm.2019.107725_bib82","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/S0028-3908(00)00005-8","article-title":"CNS plasticity and assessment of forelimb sensorimotor outcome in unilateral rat models of stroke, cortical ablation, parkinsonism and spinal cord injury","volume":"39","author":"Schallert","year":"2000","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2019.107725_bib83","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0028-3908(96)00160-8","article-title":"LY354740 is a potent and highly selective group II metabotropic glutamate receptor agonist in cells expressing human glutamate receptors","volume":"36","author":"Schoepp","year":"1997","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2019.107725_bib84","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.pneurobio.2011.10.005","article-title":"Glutamatergic mechanisms in the dyskinesias induced by pharmacological dopamine replacement and deep brain stimulation for the treatment of Parkinson's disease","volume":"96","author":"Sgambato-Faure","year":"2012","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.neuropharm.2019.107725_bib85","doi-asserted-by":"crossref","first-page":"665","DOI":"10.2147\/TCRM.S144481","article-title":"Amantadine extended-release capsules for levodopa-induced dyskinesia in patients with Parkinson's disease","volume":"14","author":"Sharma","year":"2018","journal-title":"Ther. Clin. Risk Manag."},{"key":"10.1016\/j.neuropharm.2019.107725_bib86","doi-asserted-by":"crossref","first-page":"3921","DOI":"10.1016\/j.bmcl.2012.04.112","article-title":"Development of a novel, CNS-penetrant, metabotropic glutamate receptor 3 (mGlu3) NAM probe (ML289) derived from a closely related mGlu5 PAM","volume":"22","author":"Sheffler","year":"2012","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.neuropharm.2019.107725_bib87","first-page":"35","article-title":"The master switch","volume":"181","author":"Singer","year":"2004","journal-title":"New Sci."},{"key":"10.1016\/j.neuropharm.2019.107725_bib88","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1002\/mds.870120616","article-title":"Entacapone enhances levodopa-induced reversal of motor disability in MPTP-treated common marmosets","volume":"12","author":"Smith","year":"1997","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuropharm.2019.107725_bib89","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1002\/mds.20317","article-title":"Multiple small doses of levodopa plus entacapone produce continuous dopaminergic stimulation and reduce dyskinesia induction in MPTP-treated drug-naive primates","volume":"20","author":"Smith","year":"2005","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuropharm.2019.107725_bib90","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1002\/mds.26659","article-title":"A phase 2A trial of the novel mGluR5\u2010negative allosteric modulator dipraglurant for levodopa\u2010induced dyskinesia in Parkinson's disease","volume":"31","author":"Tison","year":"2016","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuropharm.2019.107725_bib91","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.neuroscience.2014.01.042","article-title":"Effect of memantine on L-DOPA-induced dyskinesia in the 6-OHDA-lesioned rat model of Parkinson's disease","volume":"265","author":"Tronci","year":"2014","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2019.107725_bib92","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1002\/mds.26112","article-title":"Depressive symptoms in Parkinson's disease are related to decreased hippocampus and amygdala volume","volume":"30","author":"van Mierlo","year":"2015","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuropharm.2019.107725_bib93","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.pbb.2008.04.010","article-title":"A 5-HT2A receptor inverse agonist, ACP-103, reduces tremor in a rat model and levodopa-induced dyskinesias in a monkey model","volume":"90","author":"Vanover","year":"2008","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2019.107725_bib94","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1212\/WNL.50.5.1323","article-title":"Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease","volume":"50","author":"Verhagen Metman","year":"1998","journal-title":"Neurology"},{"key":"10.1016\/j.neuropharm.2019.107725_bib95","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1002\/mds.21073","article-title":"Pharmacological characterization of psychosis-like behavior in the MPTP-lesioned nonhuman primate model of Parkinson's disease","volume":"21","author":"Visanji","year":"2006","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuropharm.2019.107725_bib96","doi-asserted-by":"crossref","first-page":"5208","DOI":"10.1021\/jm400439t","article-title":"Discovery of (R)-(2-fluoro-4-((-4-methoxyphenyl)ethynyl)phenyl) (3-hydroxypiperidin-1-yl)methanone (ML337), an mGlu3 selective and CNS penetrant negative allosteric modulator (NAM)","volume":"56","author":"Wenthur","year":"2013","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.neuropharm.2019.107725_bib97","doi-asserted-by":"crossref","first-page":"6441","DOI":"10.1073\/pnas.1819540116","article-title":"(2R, 6R)-hydroxynorketamine exerts mGlu2 receptor-dependent antidepressant actions","volume":"116","author":"Zanos","year":"2019","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.neuropharm.2019.107725_bib98","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.brainres.2003.08.065","article-title":"Pharmacokinetics of L-dopa in plasma and extracellular fluid of striatum in common marmosets","volume":"993","author":"Zhang","year":"2003","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2019.107725_bib99","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.cmpb.2010.01.007","article-title":"PKSolver: an add-in program for pharmacokinetic and pharmacodynamic data analysis in microsoft excel","volume":"99","author":"Zhang","year":"2010","journal-title":"Comput. Methods Progr. Biomed."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390819302849?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390819302849?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,23]],"date-time":"2019-09-23T00:42:27Z","timestamp":1569199347000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390819302849"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":99,"alternative-id":["S0028390819302849"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2019.107725","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Activation of mGlu2\/3 receptors, a novel therapeutic approach to alleviate dyskinesia and psychosis in experimental parkinsonism","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2019.107725","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107725"}}